-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Chemotherapy-Induced Thrombocytopenia

Program: Education Program
Session: Managing Thrombocytopenia in Challenging Situations
Hematology Disease Topics & Pathways:
Clinical Trials, Bleeding and Clotting, Biological therapies, Antibody Therapy, Adults, Non-Biological therapies, Workforce, Health Outcomes Research, Chemotherapy, Elderly, Diversity, Equity, and Inclusion (DEI) , drug development, Diseases, thrombocytopenias, Therapies, Young Adults, Study Population, Clinical Practice (e.g. Guidelines, Health Outcomes and Services, and Survivorship, Value; etc.)
Saturday, December 10, 2022, 4:00 PM-5:15 PM

Hanny Al-Samkari, MD

Division of Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA

Disclosures: Al-Samkari: Moderna: Consultancy; Forma: Consultancy; Amgen: Research Funding; Dova: Consultancy, Research Funding; argenx: Consultancy; Rigel: Consultancy; Novartis: Consultancy; Sobi: Consultancy, Research Funding; Agios: Consultancy, Research Funding.

OffLabel Disclosure: Romiplostim, eltrombopag, avatrombopag, hetrombopag for chemotherapy-induced thrombocytopenia

Previous Presentation | Next Presentation >>